

Cytosorbents Corp  
Form 8-K  
December 18, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): December 18, 2014

**CYTOSORBENTS CORPORATION**

(Exact name of registrant as specified in its charter)

**Delaware** **000-51038** **98-0373793**  
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

**7 Deer Park Drive, Suite K,**  
**Monmouth Junction, New Jersey 08852**  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(732) 329-8885**

**Not Applicable**

(Former name or former address, if changed since last report.)

Edgar Filing: Cytosorbents Corp - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On December 18, 2014, CytoSorbents Corporation, a Delaware corporation (the "Company"), issued a press release announcing the transfer of the Company's common stock, \$0.001 par value per share (the "Common Stock"), from the OTCQB Marketplace to the NASDAQ Stock Market LLC (the "NASDAQ Capital Market"). The Company expects trading on the NASDAQ Capital Market to begin on or about December 23, 2014 under the trading symbol "CTSO." The Company's Common Stock has been trading on the OTCQB Marketplace since August 9, 2006.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

**Exhibit No. Description**

99.1 Press Release of the Company, dated December 18, 2014.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 18, 2014 CYTOSORBENTS  
CORPORATION

By: /s/ Dr. Phillip P. Chan

Name: Dr. Phillip P. Chan  
President and

Title:  
Chief Executive Officer